Navigation Links
ULURU Inc. Reports Second Quarter 2013 Financial Results
Date:8/15/2013

ADDISON, Texas, Aug. 15, 2013 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR) today announced its financial results for the second quarter ended June 30, 2013 and provided a review of its operating activities.

During the second quarter continued progress was made towards the expansion of commercialization of Altrazeal® in international markets:

  • Orders were received from 4 new markets, and production was initiated for the following;
  • Czech Republic, Slovakia, Portugal and South Africa;
  • Advanced discussions on the expansion of strategic relationships for major territories; and
  • Initiated a controlled clinical study to demonstrate the cost effectiveness of Altrazeal®.
  • Commenting on the business activities, Kerry P. Gray, President and CEO, stated, "Our previous guidance for revenue growth and positive cash flow in the fourth quarter remains unchanged. Our international partnership activities have now been expanded to include Latin America and Asia. These activities will further accelerate our global growth. We remain focused on achieving our commercialization objectives for the upcoming 18 months of marketing Altrazeal® in 50 markets and we believe we are on track to achieve this objective. Activities have also commenced to further enhance the clinical package supporting Altrazeal® by undertaking additional controlled studies to demonstrate clinical benefit and cost advantage."  

    For the second quarter of 2013, the Company reported a net loss of $0.8 million, or $0.06 per share, compared with a net loss of $0.9 million, or $0.11 per share, for the same period last year.  For the six months ended June 30, 2013, the reported net loss was $1.5 million, or $0.12 per share, compared with a net loss of $1.7 million, or $0.21 per share, for the same period last year.

    Commenting on the financial results Kerry P. Gray, President
    '/>"/>

    SOURCE ULURU Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. ULURU Inc. Announces Conference Call To Discuss Financial Results For The Second Quarter Ended June 30, 2013
    2. ULURU Inc. Reports First Quarter 2013 Financial Results
    3. ULURU Inc. Announces Conference Call To Discuss Financial Results For The First Quarter Ended March 31, 2013
    4. ULURU Inc. Reports Financial Results For Fourth Quarter And Year Ending December 31, 2012
    5. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2012 and to Provide a Business Update
    6. ULURU Inc. Business Update And Outlook
    7. ULURU Inc. Announces Closing Of $440,000 Private Placement
    8. ULURU Inc. Reports Third Quarter 2012 Financial Results
    9. ULURU Inc. Announces The First Shipment Of Veterinary Product
    10. ULURU Inc. Announces First Order Of Altrazeal For European Launch
    11. ULURU Inc. Reports Second Quarter 2012 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/2/2014)... Oct. 2, 2014  Perrigo Company plc (NYSE: ... laws of Ireland (the " Company ... (the "Exchange Offer") up to $500,000,000 of its new 1.30% ... $600,000,000 of its new 2.30% Senior Notes due 2018 (the ... Senior Notes due 2023 (the " 2023 Exchange Notes ") ...
    (Date:10/2/2014)...   Softworld, Inc. announced today the launch of ... on the specific needs of pharmaceutical, biotech, and medical ... been highly successful in the clinical domain, the team ... the quality, regulatory, and validation space. ... the current Biometric team and the newly created Life ...
    (Date:10/2/2014)... , Oct. 2, 2014  Isis Pharmaceuticals, ... following webcast:What: , Webcast and conference call to ... 2 clinical studies of ISIS-SMN Rx in ... which will be presented on the morning (CEST) ... World Muscle Society in Berlin, GermanyWhen:Friday, October 10 ...
    Breaking Medicine Technology:Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 4Softworld, Inc. Launches Strategic Division Dedicated to Life Sciences Consulting 2Isis Pharmaceuticals to Host Webcast to Discuss ISIS-SMN Rx Results Presented at the World Muscle Society Congress 2
    ... - Data From Phase 3 Study Presented at ... Wyeth,Pharmaceuticals, a division of Wyeth (NYSE: WYE ... clinical trial that show patients with relapsed,and/or refractory ... treated with the mTOR (mammalian target of rapamycin) ...
    ... Show 100-Fold More Radiation Delivered to Tumor as Compared ... to Other Organs-, -All Patients ... ... TUSTIN, Calif., May 31 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported that ...
    Cached Medicine Technology:New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 2New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 3New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 4New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 5New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 6Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 2Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 3Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 4Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 5
    (Date:10/2/2014)... (PRWEB) October 02, 2014 Recently, BambooIndustry.com, ... unveiled its new collection of bamboo floors . ... for a lot of its products at the moment. ... is up to 26 percent off. The promotion will ... bamboo floors ( http://www.bambooindustry.com ) are all made by ...
    (Date:10/2/2014)... 02, 2014 Originally considered alternative ... is becoming increasingly popular with consumers. This has ... Poultry Farming industry in Australia. According to ... organic meat has surged over the past five ... the farming level.” Over the five years through ...
    (Date:10/2/2014)... have pinpointed a molecule that may trigger potentially life-threatening ... say this finding could offer a target for new ... Most asthma attacks (80 percent to 90 percent) are ... the British researchers. Most of these are rhinoviruses, which ... The researchers found that a specific molecule called IL-25 ...
    (Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... of developing celiac disease isn,t reduced by breast-feeding. Nor will ... gluten to an infant,s diet help prevent celiac disease. ... studies in the Oct. 2 New England Journal of ... that a child could avoid celiac disease if mothers breast-feed ...
    (Date:10/2/2014)... by scientists at The University of Nottingham could lead ... painkiller. , A drug resulting from the research, published ... offer new hope to sufferers of chronic pain conditions ... painkillers are currently available. , The work, led by ... Sciences, in collaboration with David Bates, Professor of Oncology ...
    Breaking Medicine News(10 mins):Health News:BambooIndustry.com: Great Bamboo Floors At Discounted Rates 2Health News:Organic Livestock and Poultry Farming in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Organic Livestock and Poultry Farming in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Organic Livestock and Poultry Farming in Australia Industry Market Research Report Now Available from IBISWorld 4Health News:New Clues to How Colds Can Spur Asthma Attacks 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:Medical discovery first step on path to new painkillers 2
    ... high-dose technology targets tumor tissue, experts say , MONDAY, ... doesn,t harm the sexual function of prostate cancer patients, ... Cancer Center in Philadelphia tracked 155 men with intermediate- ... (IMRT), a technique that more precisely targets the tumor. ...
    ... The implementation of the Physical Agents Directive 2004/40/EC ... diagnosis and treatment Europe wide. Last Fridays publicly ... brakes on a feared future for Magnetic Resonance ... dialogue prior to policy is paramount , ...
    ... emerging threats to global health and ... diseases, NEW YORK, Oct. 29 The ... achievements in public health. However, the,increased incidence and ... and the re-emergence of tuberculosis, present critical,health challenges ...
    ... major study published in the November,2007 edition of the ... who completed a study using the Brava System increased,their ... breast size. This key,finding was based on a medical ... M.D. and Alexandra Kaider, M. Sc. The study is ...
    ... reminder program, TORONTO, Oct. 29 /PRNewswire/ - ... Today! reminder program for its Linessa(R) and,Nuvaring(R) contraceptive ... that helps them remember their contraceptives and,Organon Canada ... and patients. Organon Canada initiated the Remind ...
    ... of the Achilles tendon can experience a reduction in ... dextrose solution, according to a recent study conducted by ... Chronic tendinosis is a common overuse injury which can ... tendons throughout the body, said Norman J. Maxwell, MD, ...
    Cached Medicine News:Health News:Prostate Cancer Radiotherapy Won't Affect Sexual Function 2Health News:Controversial physical agents directive postponed 2Health News:Charlie Rose Science Series to Focus on the Challenge of Researching and Implementing Effective Treatments for Diseases of the Developing World 2Health News:Charlie Rose Science Series to Focus on the Challenge of Researching and Implementing Effective Treatments for Diseases of the Developing World 3Health News:Charlie Rose Science Series to Focus on the Challenge of Researching and Implementing Effective Treatments for Diseases of the Developing World 4Health News:Newly Published Study in Leading Medical Journal Further Confirms the Brava System's Non-Surgical Breast Enhancement Effectiveness 2Health News:Telecommunications Technology Boosts Revenue Generation by Billions and Builds Positive Brand Experience 2Health News:Telecommunications Technology Boosts Revenue Generation by Billions and Builds Positive Brand Experience 3Health News:Ultrasound-guided injections help ease chronic Achilles tendon pain 2
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: